2 Stocks That Could Soar Again in 2025
Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT). Both saw their shares more than double in 2024, thanks to strong clinical progress. While these two drugmakers still don't have any approved products on the market, both could still see above-average returns in 2025. Let's look deeper at Viking's and Summit's prospects this year and beyond.
Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy. VK2735 is a dual GLP-1/GIP medicine, the same class as Eli Lilly's Zepbound. While that doesn't guarantee success, the company could make even more progress in 2025.
Viking Therapeutics should start phase 3 trials for this candidate and for VK2809, a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH) that also aced phase 2 studies.
Source Fool.com
